.Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD08_MetforminAndVildagliptin.MetforminAndVildagliptin .Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BD08_MetforminAndVildagliptin.MetforminAndVildagliptin| name: | MetforminAndVildagliptin | |
| ATC code: | A10BD08 | |
| route: | oral | |
| compartments: | 1 | |
| dosage: | 1050 | mg |
| volume of distribution: | 116 | L |
| clearance: | 441 | mL/min |
| other parameters in model implementation | ||
Metformin and vildagliptin is a fixed-dose combination medication used in the management of type 2 diabetes mellitus, particularly when monotherapy with either component alone does not provide adequate glycemic control. Metformin is a biguanide that decreases hepatic glucose production and improves insulin sensitivity, while vildagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels, thereby enhancing glucose-dependent insulin secretion.
Pharmacokinetic parameters reported for healthy adult subjects after a single oral dose of fixed-dose metformin/vildagliptin tablets (typically 50 mg vildagliptin + 1000 mg metformin).
He, YL (2012). Clinical pharmacokinetics and pharmacodynamics of vildagliptin. Clinical pharmacokinetics 51(3) 147–162. DOI:10.2165/11598080-000000000-00000 PUBMED:https://pubmed.ncbi.nlm.nih.gov/22339447